Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Preveceutical Medical Inc (PRVCF)

Preveceutical Medical Inc (PRVCF)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Preveceutical Medical Inc 885 Cambie Street Suite 2500 Vancouver A1 V6B 0R6 CAN

www.preveceutical.com P: 604-416-7777

Description:

PreveCeutical Medical Inc. is a health sciences company which develops preventive therapies utilizing organic and nature identical products. The company's research and development programs includes dual gene therapy for curative and prevention therapies for diabetes and obesity; a Sol-gel platform for nose to brain delivery of medical compounds including cannabinoids; Nature Identical (TM) peptides for treatment of ailments; non-addictive analgesic peptides, fentanyl and oxycodone and a therapeutic product for treating athletes who suffer from concussions. It sells CELLB9(R), an Immune System Booster. CELLB9(R) is an oral solution containing polarized and potentiated essential minerals extracted from a novel peptide obtained from Caribbean Blue Scorpion venom. PreveCeutical Medical Inc. is based in Vancouver, Canada.

Key Statistics

Overview:

Market Capitalization, $K 7,762
Enterprise Value, $K 10,292
Shares Outstanding, K 535,303
Annual Sales, $ 0 K
Annual Net Income, $ -1,140 K
Last Quarter Sales, $ 0 K
Last Quarter Net Income, $ -180 K
EBIT, $ -620 K
EBITDA, $ -610 K
60-Month Beta 0.63
% of Institutional Shareholders 0.00%
Float, K 535,303
% Float 100.00%
Short Volume Ratio 0.37

Growth:

1-Year Return -48.36%
3-Year Return -34.09%
5-Year Return -69.34%
5-Year Revenue Growth 0.00%
5-Year Earnings Growth 0.00%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings 0.00 on 11/21/23
Latest Earnings Date 06/04/24
Earnings Per Share ttm 0.00
Annual Dividend Yield 0.00%
Dividend Payout Ratio 0.00%
Most Recent Split 5-1 on 05/23/18

PRVCF Ratios

Ratio
Price/Earnings ttm 0.00
Price/Earnings forward N/A
Price/Earnings to Growth N/A
Return-on-Equity % 0.00%
Return-on-Assets % 0.00%
Profit Margin % 0.00%
Debt/Equity -0.70
Price/Sales N/A
Price/Cash Flow N/A
Price/Book N/A
Book Value/Share -0.01
Interest Coverage -6.13
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar